Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hepatitis

  Free Subscription


Articles published in J Viral Hepat

Retrieve available abstracts of 241 articles:
HTML format
Text format



Single Articles


    August 2017
  1. SERPER M, Forde KA, Kaplan DE
    Rare clinically significant hepatic events and hepatitis B reactivation occur more frequently following rather than during direct-acting antiviral therapy for chronic hepatitis C: data from a national US cohort.
    J Viral Hepat. 2017 Aug 28. doi: 10.1111/jvh.12784.
    PubMed     Text format     Abstract available


  2. ZHENG H, Cui FQ, Wang FZ, Huang LF, et al
    The epidemiology of hepatitis B virus infection in women of reproductive age in highly endemic areas in China.
    J Viral Hepat. 2017 Aug 23. doi: 10.1111/jvh.12757.
    PubMed     Text format     Abstract available


  3. SHAFRAN SD, Shaw D, Charafeddine M, Agarwal K, et al
    Efficacy and Safety Results of Patients with HCV Genotype 2 or 3 Infection Treated with Ombitasvir/Paritaprevir/ritonavir and Sofosbuvir with or without Ribavirin (QUARTZ II-III).
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12782.
    PubMed     Text format     Abstract available


  4. KITRINOS KM, Corsa AC, Worth A, Hedskog C, et al
    Nonstructural Protein 5A (NS5A) Resistance Profile in Patients with Chronic Hepatitis C Treated with Ledipasvir-Containing Regimens Without Sofosbuvir.
    J Viral Hepat. 2017 Aug 20. doi: 10.1111/jvh.12783.
    PubMed     Text format     Abstract available


  5. KRAMER JR, El-Serag HB, Taylor TJ, White DL, et al
    Hepatitis C virus-related complications are increasing in women veterans: A national cohort study.
    J Viral Hepat. 2017 Aug 16. doi: 10.1111/jvh.12728.
    PubMed     Text format     Abstract available


  6. BARONE M, Iannone A, Shahini E, Ippolito AM, et al
    A different perspective on sofosbuvir-ledipasvir treatment of patients with HCV genotype 1b cirrhosis: the ITAL-C network study.
    J Viral Hepat. 2017 Aug 8. doi: 10.1111/jvh.12765.
    PubMed     Text format     Abstract available


  7. MERCHANTE N, Aldamiz-Echevarria T, Garcia-Alvarez M, Rivero-Juarez A, et al
    Bacterial translocation and clinical progression of HCV-related cirrhosis in HIV-infected patients.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12769.
    PubMed     Text format     Abstract available


  8. VON FELDEN J, Scheurich C, Yamamura J, Brainard DM, et al
    Successful treatment of chronic hepatitis C with ground ledipasvir / sofosbuvir in a patient with Crohn's disease and short bowel syndrome.
    J Viral Hepat. 2017 Aug 7. doi: 10.1111/jvh.12768.
    PubMed     Text format     Abstract available


  9. FOURNIER C, Hoffmann TW, Morel V, Descamps V, et al
    Claudin-1, miR-122 and Apolipoprotein E transduction improves the permissivity of SNU-182, SNU-398 and SNU-449 Hepatoma cells to Hepatitis C Virus.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12767.
    PubMed     Text format     Abstract available


  10. HUI RW, Seto WK, Cheung KS, Mak LY, et al
    Inverse relationship between hepatic steatosis and hepatitis B viremia: results of a large case control study.
    J Viral Hepat. 2017 Aug 3. doi: 10.1111/jvh.12766.
    PubMed     Text format     Abstract available


    July 2017
  11. HALLAGER S, Ladelund S, Kjaer MS, Madsen LG, et al
    Hepatocellular carcinoma in patients with chronic hepatitis C and cirrhosis in Denmark: a nationwide cohort study.
    J Viral Hepat. 2017 Jul 27. doi: 10.1111/jvh.12764.
    PubMed     Text format     Abstract available


  12. JACKA B, Bray B, Applegate TL, Marshall BD, et al
    Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12758.
    PubMed     Text format     Abstract available


  13. SOLOMON SS, Sulkowski MS, Amrose P, Srikrishnan AK, et al
    Directly Observed Therapy of Sofosbuvir/Ribavirin +/- Peginterferon with minimal monitoring for the treatment of chronic hepatitis C in people with a history of drug use in Chennai, India (C-DOT).
    J Viral Hepat. 2017 Jul 18. doi: 10.1111/jvh.12761.
    PubMed     Text format     Abstract available


  14. CHAKRABARTY G, Bruce M, Horner M, Wang B, et al
    Can Quantitative Hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?
    J Viral Hepat. 2017 Jul 14. doi: 10.1111/jvh.12756.
    PubMed     Text format     Abstract available


  15. CALVARUSO V, Ferraro D, Licata A, Bavetta MG, et al
    HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct acting antivirals.
    J Viral Hepat. 2017 Jul 13. doi: 10.1111/jvh.12754.
    PubMed     Text format     Abstract available


  16. GARDNER SD, Kim J, Baptiste-Brown S, Lopez V, et al
    GSK2878175, a pan-genotypic non-nucleoside NS5B polymerase inhibitor, in healthy and treatment-naive chronic hepatitis C subjects.
    J Viral Hepat. 2017 Jul 10. doi: 10.1111/jvh.12753.
    PubMed     Text format     Abstract available


  17. AL-QAHTANI AA, Al-Anazi MR, Nazir N, Wani K, et al
    Association of Single Nucleotide Polymorphisms in MicroRNAs with Susceptibility to Hepatitis B Virus Infection and HBV-related Liver Complications: A Study in a Saudi Arabian Population.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12749.
    PubMed     Text format     Abstract available


  18. SALAZAR-VIZCAYA L, Kouyos RD, Fehr J, Braun D, et al
    On the potential of a short-term intensive intervention to interrupt HCV transmission in HIV-positive men who have sex with men: a mathematical modelling study.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12752.
    PubMed     Text format     Abstract available


  19. LI Q, Lu C, Li W, Huang Y, et al
    The gamma-glutamyl transpeptidase to albumin ratio predicts significant fibrosis and cirrhosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jul 7. doi: 10.1111/jvh.12751.
    PubMed     Text format     Abstract available


    June 2017
  20. BENOVA L, Awad SF, Abu-Raddad LJ
    Estimate of vertical transmission of Hepatitis C virus in Pakistan in 2007 and 2012 birth cohorts.
    J Viral Hepat. 2017 Jun 29. doi: 10.1111/jvh.12748.
    PubMed     Text format     Abstract available


  21. LI Y, Li Y, Zhang L, Li W, et al
    Hepatitis C virus infection and risk of multiple myeloma: evidence from a meta-analysis based on 17 case-control studies.
    J Viral Hepat. 2017 Jun 28. doi: 10.1111/jvh.12742.
    PubMed     Text format     Abstract available


  22. SIDDIQUI ZI, Farooqui SR, Azam SA, Afroz M, et al
    A comparative study of hepatitis B virus X protein mutants K130M, V131I and KV130/131MI to investigate their roles in fibrosis, cirrhosis and hepatocellular carcinoma.
    J Viral Hepat. 2017 Jun 27. doi: 10.1111/jvh.12747.
    PubMed     Text format     Abstract available


  23. TENG W, Hsieh YC, Lui KW, Chen WT, et al
    Eradication of hepatitis C virus profoundly prolongs survival in hepatocellular carcinoma patients receiving transarterial chemoembolization.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12745.
    PubMed     Text format     Abstract available


  24. SCHIAVINATO A, Zanetto A, Pantano G, Tosato F, et al
    Polyclonal and monoclonal B-lymphocytes response in HCV patients treated with direct-acting antiviral agents.
    J Viral Hepat. 2017 Jun 22. doi: 10.1111/jvh.12746.
    PubMed     Text format     Abstract available


  25. DE LA TORRE AN, Castaneda I, Ahmad M, Ekholy N, et al
    Audio Computer Assisted Survey Interview and Patient Navigation to Increase Chronic Viral Hepatitis Diagnosis and Linkage to Care in Urban Health Clinics.
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12744.
    PubMed     Text format     Abstract available


  26. DIRKS M, Pflugrad H, Weissenborn K
    Response to letter to the editor: Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 21. doi: 10.1111/jvh.12740.
    PubMed     Text format     Abstract available


  27. YANG R, Gui X, Xiong Y, Gao S, et al
    Long-term Follow-up of Patients Triply Infected with HIV and Hepatitis B and C Viruses in a Comprehensive Hospital in Central China.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12739.
    PubMed     Text format     Abstract available


  28. GADE A
    Persistent neuropsychiatric impairment in HCV patients - or educational mismatch?!
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12743.
    PubMed     Text format     Abstract available


  29. KAWAGISHI N, Suda G, Onozawa M, Kimura M, et al
    Comparing the risk of hepatitis B virus reactivation between direct-acting antiviral therapies and interferon-based therapies for hepatitis C.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12737.
    PubMed     Text format     Abstract available


  30. STELMA F, van der Ree MH, Jansen L, Peters MW, et al
    HBsAg loss after peginterferon and nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up.
    J Viral Hepat. 2017 Jun 20. doi: 10.1111/jvh.12738.
    PubMed     Text format     Abstract available


  31. JOHNSON K, Green PK, Ioannou GN
    Implications of HCV RNA level at week 4 of direct antiviral treatments for Hepatitis C.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12731.
    PubMed     Text format     Abstract available


  32. WONG RJ, Nguyen MT, Trinh HN, Chan C, et al
    Hepatitis B Surface Antigen Loss and Sustained Viral Suppression in Asian Chronic Hepatitis B Patients: A Community-Based Real World Study.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12736.
    PubMed     Text format     Abstract available


  33. KIM HS, Rotundo L, Yang JD, Kim D, et al
    Racial/ethnic disparities in the prevalence and awareness of Hepatitis B virus infection and immunity in the United States.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12735.
    PubMed     Text format     Abstract available


  34. EL SHERIF O, Afhdal N, Curry M
    No one size fits all - shortening duration of therapy with direct acting antivirals for Hepatitis C genotype 1 infection.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12734.
    PubMed     Text format     Abstract available


  35. NING L, Lin W, Hu X, Rong F, et al
    Prevalence of chronic kidney disease in patients with chronic hepatitis B: A cross-sectional survey.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12733.
    PubMed     Text format     Abstract available


  36. LOK AS, Ganova-Raeva L, Cloonan Y, Punkova L, et al
    Prevalence of Hepatitis B Antiviral Drug Resistance Variants in North American Patients with Chronic Hepatitis B Not Receiving Antiviral Treatment.
    J Viral Hepat. 2017 Jun 5. doi: 10.1111/jvh.12732.
    PubMed     Text format     Abstract available


  37. SHARMA S, Kumar A, Kar P, Agarwal S, et al
    Risk factors for vertical transmssion of hepatitis E virus infection.
    J Viral Hepat. 2017 Jun 1. doi: 10.1111/jvh.12730.
    PubMed     Text format     Abstract available


    May 2017
  38. BROUWER WP, van der Meer AJ, Boonstra A, Plompen EPC, et al
    Prediction of long-term clinical outcome in a diverse chronic hepatitis b population: role of the PAGE-B score.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12727.
    PubMed     Text format     Abstract available


  39. FITCH DN, Dharod A, Campos CL, Nunez M, et al
    Use of Electronic Health Record Clinical Decision Support Tool for HCV Birth Cohort Screening.
    J Viral Hepat. 2017 May 24. doi: 10.1111/jvh.12729.
    PubMed     Text format     Abstract available


  40. ROB B, Moreno C, Van Vlierberghe H, Bourgeois S, et al
    The risk of early occurrence and recurrence of hepatocellular carcinoma in hepatitis C infected patients treated with direct acting antivirals with and without Pegylated Interferon: A Belgian experience.
    J Viral Hepat. 2017 May 15. doi: 10.1111/jvh.12726.
    PubMed     Text format     Abstract available


  41. OSIBOGUN O, Ogunmoroti O, Michos ED, Spatz ES, et al
    HIV/HCV Co-infection and the risk of Cardiovascular Disease: A Meta-analysis.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12725.
    PubMed     Text format     Abstract available


  42. MCLEOD A, Cullen BL, Hutchinson SJ, Roy KM, et al
    Limited Impact of Awareness-Raising Campaigns on Hepatitis C Testing Practices among General Practitioners.
    J Viral Hepat. 2017 May 14. doi: 10.1111/jvh.12724.
    PubMed     Text format     Abstract available


  43. KIM GA, Han S, Kim HD, An J, et al
    Higher Risk of Hepatocellular Carcinoma in Chronic Hepatitis B vs Chronic Hepatitis C after Achievement of Virologic Response.
    J Viral Hepat. 2017 May 12. doi: 10.1111/jvh.12723.
    PubMed     Text format     Abstract available


  44. WEDEMEYER H, Craxi A, Zuckerman E, Dieterich D, et al
    Real-World Effectiveness of Ombitasvir/Paritaprevir/Ritonavir +/- Dasabuvir +/- Ribavirin in Patients with HCV Genotype 1 or 4 Infection: a Meta-Analysis.
    J Viral Hepat. 2017 May 8. doi: 10.1111/jvh.12722.
    PubMed     Text format     Abstract available


  45. SHAWA IT, Felmlee DJ, Hegazy D, Sheridan DA, et al
    Exploration of potential mechanisms of HCV resistance in exposed uninfected intravenous drug users.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12720.
    PubMed     Text format     Abstract available


  46. HLAING NKT, Mitrani RA, Aung ST, Phyo WW, et al
    Safety and Efficacy of Sofosbuvir-Based DAA Regimens for Hepatitis C Virus Genotypes 1 - 4 and 6 in Myanmar: Real-world experience.
    J Viral Hepat. 2017 May 5. doi: 10.1111/jvh.12721.
    PubMed     Text format     Abstract available


  47. GANE E, Nahass R, Luketic V, Asante-Appiah E, et al
    Efficacy of 12 or 18 weeks of elbasvir plus grazoprevir with ribavirin in treatment-naive, non-cirrhotic HCV genotype 3-infected patients.
    J Viral Hepat. 2017 May 4. doi: 10.1111/jvh.12719.
    PubMed     Text format     Abstract available


    April 2017
  48. STEININGER K, Boyd A, Dupke S, Krznaric I, et al
    HIV-positive men who have sex with men are at high risk of development of significant liver fibrosis after an episode of acute hepatitis C.
    J Viral Hepat. 2017 Apr 25. doi: 10.1111/jvh.12707.
    PubMed     Text format     Abstract available


  49. LAARIBI AB, Bortolotti D, Hannachi N, Mehri A, et al
    Increased levels of soluble HLA-G molecules in Tunisian patients with chronic hepatitis B infection.
    J Viral Hepat. 2017 Apr 21. doi: 10.1111/jvh.12718.
    PubMed     Text format     Abstract available


  50. CAI YJ, Dong JJ, Wang XD, Huang SS, et al
    A diagnostic algorithm for assessment of liver fibrosis by liver stiffness measurement in patients with chronic hepatitis B.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12715.
    PubMed     Text format     Abstract available


  51. PAPASAVVAS E, Azzoni L, Yin X, Liu Q, et al
    HCV viremia associates with NK cell activation and dysfunction in anti retroviral HIV/HCV co-infected subjects.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12714.
    PubMed     Text format     Abstract available


  52. DE GROEN RA, Groothuismink ZMA, van Oord G, Kootstra NA, et al
    NK cells in self-limited HCV infection exhibit a more extensively differentiated, but not memory-like, repertoire.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12716.
    PubMed     Text format     Abstract available


  53. MGAIETH S, Kemp W, Gow P, Fink M, et al
    Impact of viral hepatitis etiology on survival outcomes in hepatocellular carcinoma: a large multi-center cohort study.
    J Viral Hepat. 2017 Apr 17. doi: 10.1111/jvh.12717.
    PubMed     Text format     Abstract available


  54. HUANG CE, Yang YH, Chen YY, Chang JJ, et al
    The impact of hepatitis B virus infection and vaccination on the development of non-Hodgkin lymphoma.
    J Viral Hepat. 2017 Apr 4. doi: 10.1111/jvh.12713.
    PubMed     Text format     Abstract available


    March 2017
  55. VUKOTIC R, Conti F, Fagiuoli S, Morelli MC, et al
    Long-term outcomes of DAAs in post-transplant advanced HCV recurrence and fibrosing cholestatic hepatitis.
    J Viral Hepat. 2017 Mar 28. doi: 10.1111/jvh.12712.
    PubMed     Text format     Abstract available


  56. BOGLIONE L, Mornese Pinna S, De Nicolo A, Cusato J, et al
    Treatment with direct-acting antiviral agents of hepatitis C virus infection in injecting drug users: a prospective study.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12711.
    PubMed     Text format     Abstract available


  57. XU JH, Wang S, Xu ZN, Yu YY, et al
    Entecavir maleate versus entecavir in Chinese chronic hepatitis B predominantly genotype B or C: results at week 144.
    J Viral Hepat. 2017 Mar 26. doi: 10.1111/jvh.12710.
    PubMed     Text format     Abstract available


  58. SU H, Shao Z, Pu Z, Wang Y, et al
    Overt and occult hepatitis B virus infection among community children in Northwest China.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12709.
    PubMed     Text format     Abstract available


  59. WELZEL TM, Hinrichsen H, Sarrazin C, Buggisch P, et al
    Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
    J Viral Hepat. 2017 Mar 25. doi: 10.1111/jvh.12708.
    PubMed     Text format     Abstract available


  60. AFDHAL N, Everson GT, Calleja JL, McCaughan GW, et al
    Effect of Viral Suppression on Hepatic Venous Pressure Gradient in Hepatitis C With Cirrhosis and Portal Hypertension.
    J Viral Hepat. 2017 Mar 10. doi: 10.1111/jvh.12706.
    PubMed     Text format     Abstract available


  61. BUTI M, Dominguez-Hernandez R, Oyaguez I, Casado MA, et al
    Cost-effectiveness analysis of ledipasvir/sofosbuvir in patients with chronic hepatitis C: treatment of patients with absence or mild fibrosis compared to patients with advanced fibrosis.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12704.
    PubMed     Text format     Abstract available


  62. YOUNG K, Liu B, Bhuket T, Younossi Z, et al
    Long Term Trends in Chronic Hepatitis B Virus Infection Associated Liver Transplantation Outcomes in the United States.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12703.
    PubMed     Text format     Abstract available


  63. CHEW KW, Bhattacharya D, Horwich TB, Yan P, et al
    Performance of the Pooled Cohort Atherosclerotic Cardiovascular Disease Risk Score in Hepatitis C Virus-infected Persons.
    J Viral Hepat. 2017 Mar 8. doi: 10.1111/jvh.12705.
    PubMed     Text format     Abstract available


  64. SHRIVASTAVA S, Wilson E, Poonia B, Tang L, et al
    Augmentation of HCV specific immunity and Sustained virological response (SVR).
    J Viral Hepat. 2017 Mar 7. doi: 10.1111/jvh.12702.
    PubMed     Text format     Abstract available


  65. CUNNINGHAM EB, Harjarizadeh B, Bretana NA, Amin J, et al
    Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study.
    J Viral Hepat. 2017 Mar 3. doi: 10.1111/jvh.12701.
    PubMed     Text format     Abstract available


  66. SMITH HL, Chung RT, Mantry P, Chapman W, et al
    Prevention of allograft HCV recurrence with peri-transplant human monoclonal antibody MBL-HCV1 combined with a single oral direct-acting antiviral: A proof-of-concept study.
    J Viral Hepat. 2017;24:197-206.
    PubMed     Text format     Abstract available


  67. TAIT JM, Wang H, Stephens BP, Miller M, et al
    Multidisciplinary managed care networks-Life-saving interventions for hepatitis C patients.
    J Viral Hepat. 2017;24:207-215.
    PubMed     Text format     Abstract available


  68. AGUILERA A, Navarro D, Rodriguez Frias F, Viciana I, et al
    Prevalence and distribution of hepatitis C virus genotypes in Spain during the 2000-2015 period (The GEHEP 005 study).
    J Viral Hepat. 2017 Mar 1. doi: 10.1111/jvh.12700.
    PubMed     Text format     Abstract available


    February 2017
  69. ROMANI S, Hosseini SM, Mohebbi SR, Boonstra A, et al
    Differential expression of innate immune response genes in clinical phases of chronic hepatitis B infection.
    J Viral Hepat. 2017 Feb 20. doi: 10.1111/jvh.12699.
    PubMed     Text format     Abstract available


  70. DASHTSEREN B, Bungert A, Bat-Ulzii P, Enkhbat M, et al
    Endemic prevalence of hepatitis B and C in Mongolia: A nationwide survey among Mongolian adults.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12697.
    PubMed     Text format     Abstract available


  71. SHAKER OG, Senousy MA
    Serum microRNAs as predictors for liver fibrosis staging in hepatitis C virus-associated chronic liver disease patients.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12696.
    PubMed     Text format     Abstract available


  72. DI BONA D, Aiello A, Colomba C, Bilancia M, et al
    KIR2DL3 and the KIR ligand groups HLA-A-Bw4 and HLA-C2 predict the outcome of hepatitis B virus infection.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12698.
    PubMed     Text format     Abstract available


  73. ZHANG W, Xie Q, Ning Q, Dou X, et al
    The role of peginterferon in nucleos(t)ide-analogue-treated chronic hepatitis B patients: a review of published literature.
    J Viral Hepat. 2017 Feb 17. doi: 10.1111/jvh.12695.
    PubMed     Text format     Abstract available


  74. GRANNAN S
    Understanding Patient Perceptions and Risk for Hepatitis C Screening.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12692.
    PubMed     Text format     Abstract available


  75. YONGHAO G, Pumei D, Jianhui Y, Jin X, et al
    A retrospective study of hepatitis B mother-to-child transmission prevention and post-vaccination serological test results of infants at risk of perinatal transmission in two counties of middle China.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12694.
    PubMed     Text format     Abstract available


  76. TAMAKI N, Kurosaki M, Kusakabe A, Orito E, et al
    Hepatitis B Surface Antigen Reduction by Switching from Long-term Nucleoside/nucleotide Analog Administration to Pegylated Interferon.
    J Viral Hepat. 2017 Feb 15. doi: 10.1111/jvh.12691.
    PubMed     Text format     Abstract available


  77. SOOMRO MH, Shi R, She R, Yang Y, et al
    Molecular and structural changes related to Hepatitis E virus (HEV) antigen and its expression in testis inducing apoptosis in Mongolian gerbil model.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12690.
    PubMed     Text format     Abstract available


  78. HSU HY, Chang MH, Ni YH, Chiang CL, et al
    Chronologic changes of serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25-year nationwide immunization in Taiwan.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12687.
    PubMed     Text format     Abstract available


  79. MEIER MA, Suslov A, Ketterer S, Heim MH, et al
    Hepatitis B Virus covalently closed circular DNA homeostasis is independent of the lymphotoxin pathway during chronic HBV infection.
    J Viral Hepat. 2017 Feb 9. doi: 10.1111/jvh.12689.
    PubMed     Text format     Abstract available


  80. INGILIZ P
    Martinello et al.,HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2017 Feb 7. doi: 10.1111/jvh.12686.
    PubMed     Text format     Abstract available


  81. EL-AKEL W, El-Sayed MH, El Kassas M, El-Serafy M, et al
    National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care.
    J Viral Hepat. 2017 Feb 1. doi: 10.1111/jvh.12668.
    PubMed     Text format     Abstract available


    January 2017
  82. ZHU MY, Zou X, Li Q, Yu DM, et al
    A novel noninvasive algorithm for the assessment of liver fibrosis in patients with chronic hepatitis B virus infection.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12682.
    PubMed     Text format     Abstract available


  83. HUNG CH, Wang JH, Lu SN, Hu TH, et al
    Hepatitis B surface antigen loss and clinical outcomes between HBeAg-negative cirrhosis patients who discontinued or continued nucleoside analog therapy.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12683.
    PubMed     Text format     Abstract available


  84. JANJUA NZ, Islam N, Wong J, Yoshida EM, et al
    Shift in disparities in Hepatitis C treatment from interferon to DAA era: A population-based cohort study.
    J Viral Hepat. 2017 Jan 27. doi: 10.1111/jvh.12684.
    PubMed     Text format     Abstract available


  85. DIRKS M, Pflugrad H, Haag K, Tillmann HL, et al
    Persistent neuropsychiatric impairment in HCV patients despite clearance of the virus?!
    J Viral Hepat. 2017 Jan 24. doi: 10.1111/jvh.12674.
    PubMed     Text format     Abstract available


  86. CHEN J, Xu CR, Xi M, Hu WW, et al
    Predictors of liver histological changes and a sustained response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12679.
    PubMed     Text format     Abstract available


  87. YU F, Zhou G, Huang K, Fan X, et al
    Serum lincRNA-p21 as a potential biomarker of liver fibrosis in chronic hepatitis B patients.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12680.
    PubMed     Text format     Abstract available


  88. MENDIZABAL M, Reddy KR
    Chronic Hepatitis C and Chronic Kidney disease: Advances, Limitations and Unchartered Territories.
    J Viral Hepat. 2017 Jan 20. doi: 10.1111/jvh.12681.
    PubMed     Text format     Abstract available


  89. FERNANDEZ-PONCE C, Munoz-Miranda JP, Arbulo-Echevarria MM, Litran R, et al
    Immune modulation by the Hepatitis C virus core protein.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12675.
    PubMed     Text format     Abstract available


  90. VEDIO A, Liu EZ, Lee AC, Salway S, et al
    Improving access to health care for chronic hepatitis B among migrant Chinese populations: a systematic mixed methods review of barriers and enablers.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12673.
    PubMed     Text format     Abstract available


  91. PLUMB ID, Bulkow LR, Bruce MG, Hennessy TW, et al
    Persistence of Antibody to Hepatitis A Virus 20 Years After Receipt of Hepatitis A Vaccine in Alaska.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12676.
    PubMed     Text format     Abstract available


  92. ZHOU S, Cella E, Zhou W, Kong WH, et al
    Population dynamics of HCV subtypes in injecting drug-users on methadone maintenance treatment in China associated with economic and health reform.
    J Viral Hepat. 2017 Jan 16. doi: 10.1111/jvh.12677.
    PubMed     Text format     Abstract available


  93. LIU Z, Jiang L, Liang G, Song E, et al
    Hepatitis B Virus Reactivation in Breast Cancer Patients Undergoing Chemotherapy: a review and meta-analysis of prophylaxis management.
    J Viral Hepat. 2017 Jan 10. doi: 10.1111/jvh.12672.
    PubMed     Text format     Abstract available


    December 2016
  94. GOEL A, Sanchez J, Paulino L, Feuille C, et al
    A systematic model improves hepatitis C virus birth cohort screening in hospital-based primary care.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12669.
    PubMed     Text format     Abstract available


  95. AYOUB H, Abu-Raddad LJ
    Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    J Viral Hepat. 2016 Dec 31. doi: 10.1111/jvh.12671.
    PubMed     Text format     Abstract available


  96. MARTINELLO M, Grebely J, Petoumenos K, Gane E, et al
    HCV reinfection incidence among individuals treated for recent infection.
    J Viral Hepat. 2016 Dec 27. doi: 10.1111/jvh.12666.
    PubMed     Text format     Abstract available


  97. PAN CQ, Yi W, Liu M, Wan G, et al
    Lamivudine therapy during the second vs the third trimester for preventing transmission of chronic hepatitis B.
    J Viral Hepat. 2016 Dec 26. doi: 10.1111/jvh.12640.
    PubMed     Text format     Abstract available


  98. THARINGER H, Rebbapragada I, Samuel D, Novikov N, et al
    Antibody-dependent and -independent uptake of HBsAg across human leukocyte subsets is similar between individuals with chronic hepatitis B Virus infection and healthy donors.
    J Viral Hepat. 2016 Dec 23. doi: 10.1111/jvh.12667.
    PubMed     Text format     Abstract available


  99. TOYODA H, Tada T, Takaguchi K, Senoh T, et al
    Differences in background characteristics of patients with chronic hepatitis C who achieved sustained virologic response with interferon-free versus interferon-based therapy and the risk of developing hepatocellular carcinoma after eradication of hepa
    J Viral Hepat. 2016 Dec 16. doi: 10.1111/jvh.12665.
    PubMed     Text format     Abstract available


  100. PERELLO C, Carrion JA, Ruiz-Antoran B, Crespo J, et al
    Effectiveness and safety of ombitasvir, paritaprevir, ritonavir +/- dasabuvir +/- ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12637.
    PubMed     Text format     Abstract available


  101. MUNOZ-GOMEZ R, Rincon D, Ahumada A, Hernandez E, et al
    Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotype 1 and 4 hepatitis C virus infection (HCV) in patients with severe renal impairment: a multicenter experience.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12664.
    PubMed     Text format     Abstract available


  102. CONTI F, Brillanti S, Buonfiglioli F, Vukotic R, et al
    Safety and efficacy of direct acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older.
    J Viral Hepat. 2016 Dec 15. doi: 10.1111/jvh.12663.
    PubMed     Text format     Abstract available


  103. ELBASHA E, Greaves W, Roth D, Nwankwo C, et al
    Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
    J Viral Hepat. 2016 Dec 13. doi: 10.1111/jvh.12639.
    PubMed     Text format     Abstract available


  104. XIONG H, Rong X, Wang M, Xu R, et al
    HBV/HCV co-infection is associated with a high level of HCV spontaneous clearance among drug users and blood donors in China.
    J Viral Hepat. 2016 Dec 12. doi: 10.1111/jvh.12644.
    PubMed     Text format     Abstract available


  105. ALONSO S, Riveiro-Barciela M, Fernandez I, Rincon D, et al
    Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12648.
    PubMed     Text format     Abstract available


  106. ALQAHTANI S, Ozaras R, Isakov V, Wyles D, et al
    Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12641.
    PubMed     Text format     Abstract available


  107. SHAH SR, Chowdhury A, Mehta R, Kapoor D, et al
    Sofosbuvir plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    J Viral Hepat. 2016 Dec 9. doi: 10.1111/jvh.12654.
    PubMed     Text format     Abstract available


  108. DING Y, Duan S, Ye R, Yang Y, et al
    More Improvement than Progression of Liver Fibrosis Following Antiretroviral Therapy in A Longitudinal Cohort of HIV-infected Patients With or Without HBV and HCV Co-infections.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12658.
    PubMed     Text format     Abstract available


  109. GIMENO-BALLESTER V, Buti M, San Miguel R, Riveiro M, et al
    Interferon-free therapies for Patients with Chronic Hepatitis C Genotype 3 Infection: A Systematic Review.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12660.
    PubMed     Text format     Abstract available


  110. GITTO S, Gamal N, Andreone P
    NS5A inhibitors for the treatment of hepatitis C infection.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12657.
    PubMed     Text format     Abstract available


  111. WARING JF, Davis JW, Dumas E, Cohen D, et al
    Epigenetic analysis of the IFNlambda3 gene identifies a novel marker for response to therapy in HCV-infected subjects.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12661.
    PubMed     Text format     Abstract available


  112. CHANG LY, Li Y, Kaplan DE
    Hepatitis C viremia reversibly maintains subset of antigen-specific T-bet+ tissue-like memory B-cells.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12659.
    PubMed     Text format     Abstract available


  113. ALAEI A, Alaei K, Waye K, Tracy M, et al
    Hepatitis C Infection and Other Drug Related Harms Among Inpatients Who Injected Drugs in Turkey.
    J Viral Hepat. 2016 Dec 7. doi: 10.1111/jvh.12662.
    PubMed     Text format     Abstract available


  114. DI BISCEGLIE AM, Lombardero M, Teckman J, Roberts L, et al
    Determination of hepatitis B phenotype using biochemical and serological markers.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12643.
    PubMed     Text format     Abstract available


  115. DURIER N, Yunihastuti E, Ruxrungtham K, Kinh NV, et al
    Chronic hepatitis C infection and liver disease in HIV-coinfected patients in Asia.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12630.
    PubMed     Text format     Abstract available


  116. KANAAN N, Raggi C, Goffin E, De Meyer M, et al
    Outcome of hepatitis B and C virus-associated hepatocellular carcinoma occurring after renal transplantation.
    J Viral Hepat. 2016 Dec 5. doi: 10.1111/jvh.12655.
    PubMed     Text format     Abstract available


  117. EMMANUEL B, Shardell MD, Tracy L, Kottilil S, et al
    Racial disparity in all-cause mortality among hepatitis C virus-infected individuals in a general US population, NHANES III.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12656.
    PubMed     Text format     Abstract available


  118. LLANERAS J, Riveiro-Barciela M, Buti M, Esteban R, et al
    Hepatitis C virus genotype 4: Genotype 1's little brother.
    J Viral Hepat. 2016 Dec 1. doi: 10.1111/jvh.12620.
    PubMed     Text format     Abstract available


    November 2016
  119. LIU Y, Tang K, Long J, Zhao C, et al
    The association between hepatitis B self-awareness and depression: Exploring the modifying effects of socio-economic factors.
    J Viral Hepat. 2016 Nov 28. doi: 10.1111/jvh.12647.
    PubMed     Text format     Abstract available


  120. XU JH, Song LW, Li N, Wang S, et al
    Baseline hepatitis B core antibody predicts treatment response in chronic hepatitis B patients receiving long-term entecavir.
    J Viral Hepat. 2016 Nov 28. doi: 10.1111/jvh.12626.
    PubMed     Text format     Abstract available


  121. ISLAM N, Krajden M, Gilbert M, Gustafson P, et al
    Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of hepatitis C: The BC Hepatitis Testers Cohort.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12650.
    PubMed     Text format     Abstract available


  122. MCDONALD SA, Innes HA, Aspinall E, Hayes PC, et al
    Prognosis of 1169 hepatitis C chronically infected patients with decompensated cirrhosis in the predirect-acting antiviral era.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12646.
    PubMed     Text format     Abstract available


  123. CHUAI X, Chen P, Chen H, Wang W, et al
    Protective efficacy and hepatitis B virus clearance in mice enhanced by cell-mediated immunity with novel prime-boost regimens.
    J Viral Hepat. 2016 Nov 25. doi: 10.1111/jvh.12649.
    PubMed     Text format     Abstract available


  124. BARTLETT SR, Wertheim JO, Bull RA, Matthews GV, et al
    A molecular transmission network of recent hepatitis C infection in people with and without HIV: Implications for targeted treatment strategies.
    J Viral Hepat. 2016 Nov 24. doi: 10.1111/jvh.12652.
    PubMed     Text format     Abstract available


  125. LAWITZ E, Poordad F, Gutierrez JA, Kakuda TN, et al
    Simeprevir, daclatasvir and sofosbuvir for hepatitis C virus-infected patients with decompensated liver disease.
    J Viral Hepat. 2016 Nov 23. doi: 10.1111/jvh.12645.
    PubMed     Text format     Abstract available


  126. JOO EJ, Chang Y, Yeom JS, Lee YG, et al
    Hepatitis B infection is associated with an increased incidence of thrombocytopenia in healthy adults without cirrhosis.
    J Viral Hepat. 2016 Nov 18. doi: 10.1111/jvh.12642.
    PubMed     Text format     Abstract available


  127. CHEN RC, Cai YJ, Wu JM, Wang XD, et al
    Usefulness of albumin-bilirubin grade for evaluation of long-term prognosis for hepatitis B-related cirrhosis.
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12638.
    PubMed     Text format     Abstract available


  128. BRUNO G, Saracino A, Fabrizio C, Scudeller L, et al
    Rapid improvement in liver fibrosis in HCV-infected patients with or without HIV infection and DAA-induced SVR: A "turning-off" effect of liver inflammation?
    J Viral Hepat. 2016 Nov 14. doi: 10.1111/jvh.12636.
    PubMed     Text format    


  129. HEZODE C
    Pan-genotypic treatment regimens for hepatitis C virus: Advantages and disadvantages in high- and low-income regions.
    J Viral Hepat. 2016 Nov 9. doi: 10.1111/jvh.12635.
    PubMed     Text format     Abstract available


  130. KHARABIAN MASOULEH S, Herzig S, Klose L, Roggenhofer E, et al
    Functional connectivity alterations in patients with chronic hepatitis C virus infection: A multimodal MRI study.
    J Viral Hepat. 2016 Nov 4. doi: 10.1111/jvh.12634.
    PubMed     Text format     Abstract available


  131. HUNDIE GB, Stalin Raj V, Gebre Michael D, Pas SD, et al
    A novel hepatitis B virus subgenotype D10 circulating in Ethiopia.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12631.
    PubMed     Text format     Abstract available


  132. RODRIGO C, Eltahla AA, Bull RA, Luciani F, et al
    Phylogenetic analysis of full-length, early infection, hepatitis C virus genomes among people with intravenous drug use: the InC3 Study.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12616.
    PubMed     Text format     Abstract available


  133. ITO H, Ando T, Nakamura M, Ishida H, et al
    Induction of humoral and cellular immune response to hepatitis B virus (HBV) vaccine can be upregulated by CpG oligonucleotides complexed with Dectin-1 ligand.
    J Viral Hepat. 2016 Nov 3. doi: 10.1111/jvh.12629.
    PubMed     Text format     Abstract available


  134. THOMPSON AJ, Bowden DS
    Vidal LL, et al. NS3 protease polymorphisms and genetic barrier to drug resistance of distinct HCV genotypes from worldwide treatment-naive subjects. JVH, 2016, 23(11): 840-849.
    J Viral Hepat. 2016;23:838-839.
    PubMed     Text format    


    October 2016
  135. ESMAEILI A, Mirzazadeh A, Carter GM, Esmaeili A, et al
    Higher incidence of HCV in females compared to males who inject drugs: A systematic review and meta-analysis.
    J Viral Hepat. 2016 Oct 28. doi: 10.1111/jvh.12628.
    PubMed     Text format     Abstract available


  136. EL RAZIKY M, Gamil M, Ashour MK, Sameea EA, et al
    Simeprevir plus sofosbuvir for eight or 12 weeks in treatment-naive and treatment-experienced hepatitis C virus genotype 4 patients with or without cirrhosis.
    J Viral Hepat. 2016 Oct 27. doi: 10.1111/jvh.12625.
    PubMed     Text format     Abstract available


  137. LAFFERTY L, Treloar C, Guthrie J, Chambers GM, et al
    Social capital strategies to enhance hepatitis C treatment awareness and uptake among men in prison.
    J Viral Hepat. 2016 Oct 24. doi: 10.1111/jvh.12627.
    PubMed     Text format     Abstract available


  138. LEE S, Ahn SH, Jung KS, Kim DY, et al
    Tenofovir versus tenofovir plus entecavir for chronic hepatitis B with lamivudine resistance and entecavir resistance.
    J Viral Hepat. 2016 Oct 20. doi: 10.1111/jvh.12623.
    PubMed     Text format     Abstract available


  139. TAPPER EB, Bacon BR, Curry MP, Dieterich DT, et al
    Real-world effectiveness for 12 weeks of ledipasvir-sofosbuvir for genotype 1 hepatitis C: the Trio Health study.
    J Viral Hepat. 2016 Oct 11. doi: 10.1111/jvh.12611.
    PubMed     Text format     Abstract available


  140. CRISAN D, Radu C, Suciu A, Leach N, et al
    Hepatitis C in nonobese nondiabetic patients: Insulin resistance and the metabolic syndrome make a difference.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12610.
    PubMed     Text format    


  141. SCHEMMERER M, Rauh C, Jilg W, Wenzel JJ, et al
    Time course of hepatitis E-specific antibodies in adults.
    J Viral Hepat. 2016 Oct 4. doi: 10.1111/jvh.12621.
    PubMed     Text format     Abstract available


  142. FEVERY B, Verbinnen T, Peeters M, Janssen K, et al
    Virology analyses of HCV genotype 4 isolates from patients treated with simeprevir and peginterferon/ribavirin in the Phase III RESTORE study.
    J Viral Hepat. 2016 Oct 3. doi: 10.1111/jvh.12614.
    PubMed     Text format     Abstract available


    September 2016
  143. SHI KQ, Zhou YY, Yan HD, Li H, et al
    Classification and regression tree analysis of acute-on-chronic hepatitis B liver failure: Seeing the forest for the trees.
    J Viral Hepat. 2016 Sep 30. doi: 10.1111/jvh.12617.
    PubMed     Text format     Abstract available


  144. WONG RJ, Nguyen MT, Trinh HN, Huynh A, et al
    Community-based real-world treatment outcomes of sofosbuvir/ledipasvir in Asians with chronic hepatitis C virus genotype 6 in the United States.
    J Viral Hepat. 2016 Sep 27. doi: 10.1111/jvh.12609.
    PubMed     Text format     Abstract available


  145. EMMANUEL B, Sidique N, Zhang X, Poonia B, et al
    Decline of cellular activation in non-B cells after rituximab treatment in hepatitis C-associated mixed cryoglobulinemia vasculitis.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12618.
    PubMed     Text format     Abstract available


  146. ELTAHLA AA, Rodrigo C, Betz-Stablein B, Grebely J, et al
    Analysis of resistance-associated substitutions in acute hepatitis C virus infection by deep sequencing across six genotypes and three continents.
    J Viral Hepat. 2016 Sep 25. doi: 10.1111/jvh.12615.
    PubMed     Text format     Abstract available


  147. LIU Y, Corsa AC, Buti M, Cathcart AL, et al
    No detectable resistance to tenofovir disoproxil fumarate in HBeAg+ and HBeAg- patients with chronic hepatitis B after 8 years of treatment.
    J Viral Hepat. 2016 Sep 23. doi: 10.1111/jvh.12613.
    PubMed     Text format     Abstract available


  148. TRIGO C, do Brasil PE, Costa MJ, de Castro L, et al
    Occult hepatitis B virus infection: clinical implications in tuberculosis treatment.
    J Viral Hepat. 2016 Sep 13. doi: 10.1111/jvh.12583.
    PubMed     Text format     Abstract available


  149. EL-BENDARY M, Neamatallah M, Esmat G, Kamel E, et al
    Associations of human leucocyte antigen class II-DQB1 alleles with hepatitis C virus infection in Egyptian population: a multicentre family-based study.
    J Viral Hepat. 2016 Sep 7. doi: 10.1111/jvh.12573.
    PubMed     Text format     Abstract available


    August 2016
  150. KEOSHKERIAN E, Hunter M, Cameron B, Nguyen N, et al
    Hepatitis C-specific effector and regulatory CD4 T-cell responses are associated with the outcomes of primary infection.
    J Viral Hepat. 2016 Aug 25. doi: 10.1111/jvh.12576.
    PubMed     Text format     Abstract available


  151. PRABDIAL-SING N, Chirwa T, Thaver J, Smuts H, et al
    Hepatitis C genotype distribution in patient and blood donor samples in South Africa for the period 2008-2012.
    J Viral Hepat. 2016 Aug 21. doi: 10.1111/jvh.12571.
    PubMed     Text format     Abstract available


  152. ASPINALL EJ, Mitchell W, Schofield J, Cairns A, et al
    A matched comparison study of hepatitis C treatment outcomes in the prison and community setting, and an analysis of the impact of prison release or transfer during therapy.
    J Viral Hepat. 2016 Aug 11. doi: 10.1111/jvh.12580.
    PubMed     Text format     Abstract available


  153. ALLARD N, Dev A, Dwyer J, Srivatsa G, et al
    Factors associated with poor adherence to antiviral treatment for hepatitis B.
    J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12582.
    PubMed     Text format     Abstract available


  154. BRAHMANIA M, Brouwer WP, Hansen T, Mazzulli T, et al
    Prevalence and risk factors for viral blipping in chronic hepatitis B patients treated with nucleos (t) ide analogues.
    J Viral Hepat. 2016 Aug 9. doi: 10.1111/jvh.12579.
    PubMed     Text format     Abstract available


  155. KNOP V, Hoppe D, Welzel T, Vermehren J, et al
    Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy.
    J Viral Hepat. 2016 Aug 8. doi: 10.1111/jvh.12578.
    PubMed     Text format     Abstract available


  156. BOYD A, Piroth L, Maylin S, Maynard-Muet M, et al
    Intensification with pegylated interferon during treatment with tenofovir in HIV-hepatitis B virus co-infected patients.
    J Viral Hepat. 2016 Aug 3. doi: 10.1111/jvh.12581.
    PubMed     Text format     Abstract available


    July 2016
  157. NISHIKAWA H, Enomoto H, Iwata Y, Kishino K, et al
    Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study.
    J Viral Hepat. 2016 Jul 31. doi: 10.1111/jvh.12575.
    PubMed     Text format     Abstract available


  158. CHEN X, Gui X, Zhang L, Huang F, et al
    Maternal anti-HBVs suppress the immune response of infants to hepatitis B vaccine.
    J Viral Hepat. 2016 Jul 29. doi: 10.1111/jvh.12572.
    PubMed     Text format     Abstract available


  159. WANG X, Gao F, Yuan G, Shi K, et al
    Ten-year follow-up analysis of chronic hepatitis C patients after getting sustained virological response to pegylated interferon-alpha and ribavirin therapy.
    J Viral Hepat. 2016 Jul 24. doi: 10.1111/jvh.12574.
    PubMed     Text format     Abstract available


  160. SWANN RE, Mandalou P, Robinson MW, Ow MM, et al
    Anti-envelope antibody responses in individuals at high risk of hepatitis C virus who resist infection.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12568.
    PubMed     Text format     Abstract available


  161. WILLEMSE SB, Baak LC, Kuiken SD, van der Sluys Veer A, et al
    Sofosbuvir plus simeprevir for the treatment of HCV genotype 4 patients with advanced fibrosis or compensated cirrhosis is highly efficacious in real life.
    J Viral Hepat. 2016 Jul 13. doi: 10.1111/jvh.12567.
    PubMed     Text format     Abstract available


  162. CHEN CM, Chen SC, Yang HY, Yang ST, et al
    Hospitalization and mortality due to hepatitis A in Taiwan: a 15-year nationwide cohort study.
    J Viral Hepat. 2016 Jul 7. doi: 10.1111/jvh.12564.
    PubMed     Text format     Abstract available


  163. MARTINOT-PEIGNOUX M, Lapalus M, Maylin S, Boyer N, et al
    Baseline HBsAg and HBcrAg titres allow peginterferon-based 'precision medicine' in HBeAg-negative chronic hepatitis B patients.
    J Viral Hepat. 2016 Jul 4. doi: 10.1111/jvh.12565.
    PubMed     Text format     Abstract available


    June 2016
  164. GHOSH S, Sow A, Guillot C, Jeng A, et al
    Implementation of an in-house quantitative real-time polymerase chain reaction method for Hepatitis B virus quantification in West African countries.
    J Viral Hepat. 2016 Jun 29. doi: 10.1111/jvh.12561.
    PubMed     Text format     Abstract available


  165. SCHEURICH C, Schulze Zur Wiesch J, Kim AY, Lewis-Ximenez L, et al
    Breadth of the HCV-specific CD4+ T-cell response in spontaneous resolvers is independent of the IL-28 haplotype.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12560.
    PubMed     Text format    


  166. KAWAKAMI Y, Imamura M, Ikeda H, Suzuki M, et al
    Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study.
    J Viral Hepat. 2016 Jun 27. doi: 10.1111/jvh.12553.
    PubMed     Text format     Abstract available


  167. FULOP B, Mihm U, Rohde P, Buggisch P, et al
    Hepatitis C viral dynamics during ribavirin priming differ according to prior treatment response and HCV type.
    J Viral Hepat. 2016 Jun 26. doi: 10.1111/jvh.12562.
    PubMed     Text format     Abstract available


  168. ZHOU YH
    Occult hepatitis B virus infection, or occult cross-contamination, in children of HBsAg-positive mothers.
    J Viral Hepat. 2016 Jun 23. doi: 10.1111/jvh.12559.
    PubMed     Text format    


  169. SHI R, Soomro MH, She R, Yang Y, et al
    Evidence of Hepatitis E virus breaking through the blood-brain barrier and replicating in the central nervous system.
    J Viral Hepat. 2016 Jun 21. doi: 10.1111/jvh.12557.
    PubMed     Text format     Abstract available


  170. YOUNOSSI ZM, Stepanova M, Sulkowski M, Naggie S, et al
    Sofosbuvir and ledipasvir improve patient-reported outcomes in patients co-infected with hepatitis C and human immunodeficiency virus.
    J Viral Hepat. 2016 Jun 13. doi: 10.1111/jvh.12554.
    PubMed     Text format     Abstract available


  171. GANE E, Ben Ari Z, Mollison L, Zuckerman E, et al
    Efficacy and safety of grazoprevir + ribavirin for 12 or 24 weeks in treatment-naive patients with hepatitis C virus genotype 1 infection.
    J Viral Hepat. 2016 Jun 12. doi: 10.1111/jvh.12552.
    PubMed     Text format     Abstract available


  172. JOO EJ, Yeom JS, Kwon MJ, Chang Y, et al
    Insulin resistance increases loss of antibody to hepatitis B surface antigen in nondiabetic healthy adults.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12556.
    PubMed     Text format     Abstract available


  173. DEBROY S, Hiraga N, Imamura M, Hayes CN, et al
    Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12551.
    PubMed     Text format     Abstract available


  174. GREBELY J, Litwin A, Dore GJ
    Addressing reimbursement disparities for direct-acting antiviral therapies for hepatitis C virus infection is essential to ensure access for all.
    J Viral Hepat. 2016 Jun 8. doi: 10.1111/jvh.12550.
    PubMed     Text format    


    May 2016
  175. WEISSENBORN K, Tillmann HL
    HCV encephalopathy - an artefact due to medical care?
    J Viral Hepat. 2016 May 26. doi: 10.1111/jvh.12547.
    PubMed     Text format     Abstract available


  176. MIZOKAMI M, Dvory-Sobol H, Izumi N, Nishiguchi S, et al
    Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12549.
    PubMed     Text format     Abstract available


  177. TESHALE EH, Xing J, Moorman A, Holmberg SD, et al
    Higher all-cause hospitalization among patients with chronic hepatitis C: the Chronic Hepatitis Cohort Study (CHeCS), 2006-2013.
    J Viral Hepat. 2016 May 15. doi: 10.1111/jvh.12548.
    PubMed     Text format     Abstract available


  178. LOWRY D, Burke T, Galvin Z, Ryan JD, et al
    Is psychosocial and cognitive dysfunction misattributed to the virus in hepatitis C infection? Select psychosocial contributors identified.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12544.
    PubMed     Text format     Abstract available


  179. LIM EJ, Chin R, Nachbur U, Silke J, et al
    Hepatitis C-induced hepatocyte apoptosis following liver transplantation is enhanced by immunosuppressive agents.
    J Viral Hepat. 2016 May 11. doi: 10.1111/jvh.12541.
    PubMed     Text format     Abstract available


  180. DEUFFIC-BURBAN S, Obach D, Canva V, Pol S, et al
    Cost-effectiveness and budget impact of interferon-free direct-acting antiviral-based regimens for hepatitis C treatment: the French case.
    J Viral Hepat. 2016 May 4. doi: 10.1111/jvh.12546.
    PubMed     Text format     Abstract available


    April 2016
  181. KATOONIZADEH A, Sharafkhah M, Ostovaneh MR, Norouzi A, et al
    Immune responses to hepatitis B immunization 10-18 years after primary vaccination: a population-based cohort study.
    J Viral Hepat. 2016 Apr 29. doi: 10.1111/jvh.12543.
    PubMed     Text format     Abstract available


  182. RAZAVI H
    Making the case for looking beyond WHO estimates for the global burden of hepatitis C and B.
    J Viral Hepat. 2016 Apr 5. doi: 10.1111/jvh.12539.
    PubMed     Text format     Abstract available


  183. EL-SERAG HB, Kramer J, Duan Z, Kanwal F, et al
    Epidemiology and outcomes of hepatitis C infection in elderly US Veterans.
    J Viral Hepat. 2016 Apr 3. doi: 10.1111/jvh.12533.
    PubMed     Text format     Abstract available


  184. PU Z, Li D, Wang A, Su H, et al
    Epidemiological characteristics of the carriers with coexistence of HBsAg and anti-HBs based on a community cohort study.
    J Viral Hepat. 2016;23:286-93.
    PubMed     Text format     Abstract available


  185. SADEGHI A, Yahyapour Y, Poortahmasebi V, Shahmoradi S, et al
    Clearance of HBV DNA in immunized children born to HBsAg-positive mothers, years after being diagnosed with occult HBV infection.
    J Viral Hepat. 2016;23:282-5.
    PubMed     Text format     Abstract available


    March 2016
  186. LU M, Li J, Rupp LB, Holmberg SD, et al
    Hepatitis C treatment failure is associated with increased risk of hepatocellular carcinoma.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12538.
    PubMed     Text format     Abstract available


  187. BASNAYAKE SK, Easterbrook PJ
    Wide variation in estimates of global prevalence and burden and death estimates from chronic HBV, HCV and coinfection with HIV in literature.
    J Viral Hepat. 2016 Mar 30. doi: 10.1111/jvh.12519.
    PubMed     Text format     Abstract available


  188. HARRIS RJ, Martin NK, Rand E, Mandal S, et al
    New treatments for hepatitis C virus (HCV): scope for preventing liver disease and HCV transmission in England.
    J Viral Hepat. 2016 Mar 29. doi: 10.1111/jvh.12529.
    PubMed     Text format     Abstract available


  189. BUNCHORNTAVAKUL C, Reddy KR
    Treat chronic hepatitis C virus infection in decompensated cirrhosis - pre- or post-liver transplantation? the ironic conundrum in the era of effective and well-tolerated therapy.
    J Viral Hepat. 2016 Mar 28. doi: 10.1111/jvh.12534.
    PubMed     Text format     Abstract available


  190. GIUDICI F, Bertisch B, Negro F, Stirnimann G, et al
    Access to therapy and therapy outcomes in the Swiss Hepatitis C Cohort Study: a person-centred approach.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12535.
    PubMed     Text format     Abstract available


  191. REN JP, Ying RS, Cheng YQ, Wang L, et al
    HCV-induced miR146a controls SOCS1/STAT3 and cytokine expression in monocytes to promote regulatory T-cell development.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12537.
    PubMed     Text format     Abstract available


  192. MO H, Hedskog C, Svarovskaia E, Sun SC, et al
    Antiviral response and resistance analysis of treatment-naive HCV-infected patients receiving single and multiple doses of GS-9190.
    J Viral Hepat. 2016 Mar 23. doi: 10.1111/jvh.12536.
    PubMed     Text format     Abstract available


  193. GRAY E, O'Leary A, Kieran JA, Fogarty E, et al
    Direct costs of interferon-based and interferon-free direct-acting antiviral regimens for the treatment of chronic hepatitis C infection.
    J Viral Hepat. 2016 Mar 21. doi: 10.1111/jvh.12532.
    PubMed     Text format     Abstract available


  194. SERVANT-DELMAS A, Abravanel F, Lefrere JJ, Lionnet F, et al
    New insights into the natural history of hepatitis E virus infection through a longitudinal study of multitransfused immunocompetent patients in France.
    J Viral Hepat. 2016 Mar 18. doi: 10.1111/jvh.12531.
    PubMed     Text format     Abstract available


  195. PERUMALSWAMI PV, Patel N, Bichoupan K, Ku L, et al
    High baseline bilirubin and low albumin predict liver decompensation and serious adverse events in HCV-infected patients treated with sofosbuvir-containing regimens.
    J Viral Hepat. 2016 Mar 17. doi: 10.1111/jvh.12530.
    PubMed     Text format     Abstract available


  196. YOUNOSSI ZM, Stepanova M, Henry L, Younossi I, et al
    Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.
    J Viral Hepat. 2016 Mar 14. doi: 10.1111/jvh.12528.
    PubMed     Text format     Abstract available


  197. RODRIGUEZ-TORRES M, Glass S, Hill J, Freilich B, et al
    GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study.
    J Viral Hepat. 2016 Mar 9. doi: 10.1111/jvh.12527.
    PubMed     Text format     Abstract available


  198. ROQUE CUELLAR MC, Garcia-Lozano JR, Sanchez B, Praena-Fernandez JM, et al
    Lymphomagenesis-related gene expression in B cells from sustained virological responders with occult hepatitis C virus infection.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12526.
    PubMed     Text format     Abstract available


  199. STELMA F, Jansen L, Sinnige MJ, van Dort KA, et al
    HLA-C and KIR combined genotype as new response marker for HBeAg-positive chronic hepatitis B patients treated with interferon-based combination therapy.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12525.
    PubMed     Text format     Abstract available


  200. RAJBHANDARI R, Barton K, Juncadella AC, Rubin AK, et al
    Discontinuity of care for mothers with chronic hepatitis B diagnosed during pregnancy.
    J Viral Hepat. 2016 Mar 4. doi: 10.1111/jvh.12524.
    PubMed     Text format     Abstract available


  201. ZAYED N, Gamal Eldeen H, Elmakhzangy H, Seif M, et al
    Therapeutic outcome of 6198 interferon-naive Egyptian patients with chronic hepatitis C: a real-life experience and lessons to be learned in DAAs' era.
    J Viral Hepat. 2016 Mar 3. doi: 10.1111/jvh.12514.
    PubMed     Text format     Abstract available


  202. VISVANATHAN K, Lang T, Ryan K, Wilson R, et al
    Toll-IL1 receptor-mediated innate immune responses vary across HBV genotype and predict treatment response to pegylated-IFN in HBeAg-positive CHB patients.
    J Viral Hepat. 2016;23:170-9.
    PubMed     Text format     Abstract available


    February 2016
  203. NINOMIYA M, Kondo Y, Kimura O, Funayama R, et al
    The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12522.
    PubMed     Text format     Abstract available


  204. PEVELING-OBERHAG J, Arcaini L, Bankov K, Zeuzem S, et al
    The anti-lymphoma activity of antiviral therapy in HCV-associated B-cell non-Hodgkin lymphomas: a meta-analysis.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12518.
    PubMed     Text format     Abstract available


  205. WOODE ME, Abu-Zaineh M, Perriens J, Renaud F, et al
    Potential market size and impact of hepatitis C treatment in low- and middle-income countries.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12516.
    PubMed     Text format     Abstract available


  206. HARRIS M, Ward E, Gore C
    Finding the undiagnosed: a qualitative exploration of hepatitis C diagnosis delay in the United Kingdom.
    J Viral Hepat. 2016 Feb 29. doi: 10.1111/jvh.12513.
    PubMed     Text format     Abstract available


  207. CHEN HH, Liu PF, Tsai HH, Yen RF, et al
    Re: Wangensteen et al. of a letter on 'Hepatitis C virus infection: a risk factor for Parkinson's disease.'
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12521.
    PubMed     Text format    


  208. WANGENSTEEN KJ, Krawitt EL, Hamill RW, Boyd JT, et al
    Hepatitis C virus infection: a risk factor for Parkinson's disease.
    J Viral Hepat. 2016 Feb 23. doi: 10.1111/jvh.12517.
    PubMed     Text format    


  209. SCHNIER C, Wild S, Kurdi Z, Povey C, et al
    Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 22. doi: 10.1111/jvh.12520.
    PubMed     Text format     Abstract available


  210. KONERMAN MA, Brown M, Zheng Y, Lok AS, et al
    Dynamic prediction of risk of liver-related outcomes in chronic hepatitis C using routinely collected data.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12509.
    PubMed     Text format     Abstract available


  211. DRAVE SA, Debing Y, Walter S, Todt D, et al
    Extra-hepatic replication and infection of hepatitis E virus in neuronal-derived cells.
    J Viral Hepat. 2016 Feb 19. doi: 10.1111/jvh.12515.
    PubMed     Text format     Abstract available


  212. AHN SH, Lim YS, Lee KS, Paik SW, et al
    A phase 3b study of sofosbuvir plus ribavirin in treatment-naive and treatment-experienced Korean patients chronically infected with genotype 2 hepatitis C virus.
    J Viral Hepat. 2016 Feb 10. doi: 10.1111/jvh.12499.
    PubMed     Text format     Abstract available


  213. HAWKS L, Norton BL, Cunningham CO, Fox AD, et al
    The Hepatitis C virus treatment cascade at an urban postincarceration transitions clinic.
    J Viral Hepat. 2016 Feb 9. doi: 10.1111/jvh.12512.
    PubMed     Text format     Abstract available


  214. GISA A, Suneetha PV, Behrendt P, Pischke S, et al
    Cross-specific T-cell responses in acute hepatitis E virus (HEV) infection.
    J Viral Hepat. 2016 Feb 8. doi: 10.1111/jvh.12495.
    PubMed     Text format     Abstract available


  215. MEISSNER EG, Kohli A, Virtaneva K, Sturdevant D, et al
    Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12510.
    PubMed     Text format     Abstract available


  216. FALADE-NWULIA O, Mehta SH, Lasola J, Latkin C, et al
    Public health clinic-based hepatitis C testing and linkage to care in baltimore.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12507.
    PubMed     Text format     Abstract available


  217. YOUNOSSI ZM, Bacon BR, Dieterich DT, Flamm SL, et al
    Disparate access to treatment regimens in chronic hepatitis C patients: data from the TRIO network.
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12506.
    PubMed     Text format     Abstract available


  218. BOGLIONE L, Cariti G, Di Perri G, D'Avolio A, et al
    Sequential therapy with entecavir and peginterferon alpha in chronic hepatitis B: for many but not for all?
    J Viral Hepat. 2016 Feb 3. doi: 10.1111/jvh.12502.
    PubMed     Text format    


  219. PAPATHEODORIDIS G, Thomas HC, Golna C, Bernardi M, et al
    Addressing barriers to the prevention, diagnosis and treatment of hepatitis B and C in the face of persisting fiscal constraints in Europe: report from a high level conference.
    J Viral Hepat. 2016;23 Suppl 1:1-12.
    PubMed     Text format     Abstract available


  220. MINA MM, Cameron B, Luciani F, Vollmer-Conna U, et al
    Natural killer cells in highly exposed hepatitis C-seronegative injecting drug users.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12511.
    PubMed     Text format     Abstract available


  221. BROERING R, Trippler M, Werner M, Real CI, et al
    Hepatic expression of proteasome subunit alpha type-6 is upregulated during viral hepatitis and putatively regulates the expression of ISG15 ubiquitin-like modifier, a proviral host gene in hepatitis C virus infection.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12508.
    PubMed     Text format     Abstract available


  222. POITEAU L, Soulier A, Rosa I, Roudot-Thoraval F, et al
    Performance of rapid diagnostic tests for the detection of antibodies to hepatitis C virus in whole blood collected on dried blood spots.
    J Viral Hepat. 2016 Feb 1. doi: 10.1111/jvh.12501.
    PubMed     Text format     Abstract available


  223. IDRISSI ME, Hachem H, Koering C, Merle P, et al
    HBx triggers either cellular senescence or cell proliferation depending on cellular phenotype.
    J Viral Hepat. 2016;23:130-8.
    PubMed     Text format     Abstract available


    January 2016
  224. STUBBS A, Naylor P, Ravindran K, Benjaram S, et al
    Racial diversity in mortality and morbidity in urban patients with hepatitis C.
    J Viral Hepat. 2016 Jan 28. doi: 10.1111/jvh.12504.
    PubMed     Text format     Abstract available


  225. VIDAL LL, Soares MA, Santos AF
    NS3 protease polymorphisms and genetic barrier to drug resistance of distinct hepatitis C virus genotypes from worldwide treatment-naive subjects.
    J Viral Hepat. 2016 Jan 18. doi: 10.1111/jvh.12503.
    PubMed     Text format     Abstract available


  226. PFLUGRAD H, Meyer GJ, Dirks M, Raab P, et al
    Cerebral microglia activation in hepatitis C virus infection correlates to cognitive dysfunction.
    J Viral Hepat. 2016 Jan 15. doi: 10.1111/jvh.12496.
    PubMed     Text format     Abstract available


  227. ORTEGA-PRIETO AM, Dorner M
    The expanding toolbox for hepatitis C virus research.
    J Viral Hepat. 2016 Jan 13. doi: 10.1111/jvh.12500.
    PubMed     Text format     Abstract available


  228. SHRESTHA A, Lama TK, Gupta BP, Sapkota B, et al
    Hepatitis E virus outbreak in postearthquake Nepal: is a vaccine really needed?
    J Viral Hepat. 2016 Jan 12. doi: 10.1111/jvh.12505.
    PubMed     Text format    


  229. VELAY A, Jeulin H, Eschlimann M, Malve B, et al
    Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.
    J Viral Hepat. 2016 Jan 6. doi: 10.1111/jvh.12498.
    PubMed     Text format     Abstract available


  230. FOSTER GR
    The Journal Of Viral Hepatitis 2016.
    J Viral Hepat. 2016;23:4.
    PubMed     Text format    


    December 2015
  231. DUARTE-ROJO A, Fischer SE, Adeyi O, Zita D, et al
    Protease inhibitors partially overcome the interferon nonresponse phenotype in patients with chronic hepatitis C.
    J Viral Hepat. 2015 Dec 29. doi: 10.1111/jvh.12494.
    PubMed     Text format     Abstract available


  232. ZHANG S, Ma Q, Liang S, Xiao H, et al
    Annual economic burden of hepatitis B virus-related diseases among hospitalized patients in twelve cities in China.
    J Viral Hepat. 2015 Dec 10. doi: 10.1111/jvh.12482.
    PubMed     Text format     Abstract available


  233. ZHOU X, Xu L, Wang W, Watashi K, et al
    Disparity of basal and therapeutically activated interferon signalling in constraining hepatitis E virus infection.
    J Viral Hepat. 2015 Dec 1. doi: 10.1111/jvh.12491.
    PubMed     Text format     Abstract available


    November 2015
  234. YOUNG KL, Huang W, Horsburgh CR, Linas BP, et al
    Eighteen- to 30-year-olds more likely to link to hepatitis C virus care: an opportunity to decrease transmission.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12489.
    PubMed     Text format     Abstract available


  235. FOSTER GR, Ferenci P, Asselah T, Mantry P, et al
    Open-label study of faldaprevir plus peginterferon and ribavirin in hepatitis C virus genotype 1-infected patients who failed placebo plus peginterferon and ribavirin.
    J Viral Hepat. 2015 Nov 17. doi: 10.1111/jvh.12485.
    PubMed     Text format     Abstract available


    August 2015
  236. ATHANASAKIS K, Petrakis I, Kyriopoulos J
    'HepConomics': cost-effective, indeed, but how can we pay for it?
    J Viral Hepat. 2015;22:682.
    PubMed     Text format    


    July 2015
  237. CHOLONGITAS E, Vasiliadis T, Goulis I, Fouzas I, et al
    Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease.
    J Viral Hepat. 2015;22:574-80.
    PubMed     Text format     Abstract available


    May 2015
  238. ZENG H, Liu H, Wan G, Wang X, et al
    Answer to 'Misdiagnosis of patients may be derived from the interfering factors and used cut-offs in indexes'.
    J Viral Hepat. 2015;22:513-4.
    PubMed     Text format    


  239. COBAN M, Sertoglu E, Kayadibi H
    Misdiagnosis of patients may be derived from the interfering factors and used cut-offs in indexes.
    J Viral Hepat. 2015;22:512.
    PubMed     Text format    


    April 2015
  240. JOHANNESSEN A
    Where we are with point-of-care testing.
    J Viral Hepat. 2015;22:362-5.
    PubMed     Text format     Abstract available


  241. CAREY I, Bruce M, Horner M, Zen Y, et al
    HBsAg plasma level kinetics: a new role for an old marker as a therapy response predictor in vertically infected children on combination therapy.
    J Viral Hepat. 2015;22:441-52.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hepatitis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: